Production method of torasemide

The synthesis of torasemite crude products through condensation reaction and performs detailed crystallization, washing and drying steps, solving the problems of lack of stability inspection data and high cost in the prior art, achieving high purity and low cost Production effect.

CN118955366APending Publication Date: 2024-11-15HUNAN SAILONG PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411041036.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing Torasemite production methods lack data on the stability of finished products, and the industrialization costs are high, and there is a lack of effective stability guarantee.

Method used

The method of synthesizing torasemine crude product by condensation reaction, the specific steps include reacting 4-(3-methylphenyl)aminopyridine-3-sulfonamide with isopropyl isocyanate under temperature control conditions, and then performing analysis. Crystallization, washing and drying steps, high-purity torasemite product is obtained by adjusting pH and temperature control.

Benefits of technology

The ideal stability and high yield of Torasemite finished products are achieved, industrialized costs are reduced, process operations are simplified, and production feasibility is improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955366A_ABST
    Figure CN118955366A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of raw material medicine preparation, in particular to a torasemide production method, which comprises a torasemide crude product synthesis step, and the torasemide crude product synthesis step comprises a condensation reaction step of carrying out a condensation reaction on a first intermediate and isopropyl isocyanate to obtain the torasemide crude product, the first intermediate is 4-(3-methylphenyl) aminopyridine-3-sulfonamide, and the second intermediate is 4-(3-methylphenyl) The condensation reaction step specifically comprises the following steps: uniformly mixing triethylamine, acetone and the first intermediate in a reaction kettle, slowly adding isopropyl isocyanate, controlling the temperature to 40-50 DEG C, and stirring to react for at least 6 hours. The finished product bulk drug has ideal stability.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of raw material drug preparation, and specifically relates to a production method of torasemide. Background Art

[0002] Torasemide is N-isopropyl-[4-(3-methyl)anilinopyridine-3-sulfonamido]carboxamide, with a chemical formula of C16H20N4O3S. It is a new generation of highly effective loop diuretics, which was launched in Germany in 1993 and in the United States the following year. In 2004, my country's SFDA approved the production of the first domestic torsemide injection (Tesunil), filling the gap in the clinical application of the drug in China. The literature currently discloses its traditional synthesis route and the improved synthesis process and improved steps based on the route.

[0003] U.S. Patent No. RE. 30633 discloses the synthesis of torasemide, the synthetic route is as follows Figure 1 .

[0004] In document 1 published in December 2009 by Zhao Shiming et al. (Zhao Shiming, et al.; Research on the Synthesis of Torsemide, [J] Fine Chemical Intermediates; Vol. 39, No. 6, December 2009), an improved synthetic process route for preparing torsemide was proposed: 45 g (0.170 mol) of 4-(3-methylphenylamino)-3-pyridinesulfonamide, 35 g (0.300 mol) of methyl isopropylcarbamate, 38 g of potassium carbonate, 500 mL of ethylene glycol diethyl ether, and 30 mL of pyridine were added to a 1 L reaction bottle, refluxed for 30 h, filtered, and the obtained solid was dissolved in water, the pH was adjusted to 5 with acetic acid, the precipitate was precipitated, filtered, and 55.6 g of torsemide crystals (crude product) were obtained, with a yield of 93.1%.

[0005] Teva Pharmaceutical Industries applied for Chinese patent 01806834.0, which disclosed a new synthesis method of torasemide intermediates and a synthesis method of torasemide. 20041078738.6 also disclosed a new synthesis method of torasemide.

[0006] Chinese patent ZL200910272388.X also discloses a method for purifying torsemide, which comprises dissolving crude torsemide in a weakly acidic solvent, raising the temperature to 85-100°C, stirring to dissolve, decolorizing and filtering, slowly cooling the filtrate to 5-30°C for crystallization, filtering and separating the crystals, and drying at 50-70°C to obtain crystals with a purity higher than 99% and an average particle size of 50-350um.

[0007] Torsemide, as a raw material, will be further processed into pharmaceutical preparations of different dosage forms such as injections and oral preparations. The preparation methods disclosed in the above-mentioned prior art have high requirements on the stability of the torsemide finished product, and no data on stability inspection is disclosed in the prior art. Summary of the invention

[0008] In view of the related art in the art, the present invention proposes to provide an alternative torsemide production method with different technical concepts, the method comprising a torsemide crude product synthesis step, the torsemide crude product synthesis step comprising a condensation reaction step of reacting a first intermediate with isopropyl isocyanate to obtain the torsemide crude product;

[0009] The first intermediate is 4-(3-methylphenyl)aminopyridine-3-sulfonamide;

[0010] The condensation reaction step specifically includes the following steps: after uniformly mixing triethylamine, acetone and the first intermediate in a reaction kettle, slowly adding isopropyl isocyanate, controlling the temperature to 40-50° C. and stirring the reaction for at least 6 hours.

[0011] The data in the test examples prove that the finished bulk drug prepared by the present invention has ideal stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 : Traditional synthetic route of torsemide.

[0013] Figure 2 : The synthesis process of crude torasemide of some embodiments;

[0014] Figure 3 : The synthesis process of the first intermediate of some embodiments;

[0015] Figure 4 : The synthesis process of the second intermediate of some embodiments;

[0016] Figure 5 : Process flow of the refining step of some embodiments. DETAILED DESCRIPTION

[0017] The following examples further illustrate the content of the present invention, but should not be construed as limiting the present invention. Without departing from the spirit and substance of the present invention, modifications or substitutions made to the methods, steps or conditions of the present invention all fall within the scope of the present invention.

[0018] Example 1

[0019] like Figure 2The embodiment comprises a step of synthesizing a crude torsemide, wherein the step of synthesizing the crude torsemide comprises a condensation reaction step of reacting a first intermediate with isopropyl isocyanate to obtain the crude torsemide;

[0020] The first intermediate is 4-(3-methylphenyl)aminopyridine-3-sulfonamide;

[0021] The condensation reaction step specifically includes the following steps: after uniformly mixing triethylamine, acetone and the first intermediate in a reaction kettle, slowly adding isopropyl isocyanate, controlling the temperature to 40-50° C. and stirring the reaction for at least 6 hours.

[0022] Example 2

[0023] After the condensation reaction step of Example 1, a crystallization step, a washing step, and a drying step are also included;

[0024] In the crystallization step, the pH of the system is adjusted to 4±0.2 with 4N hydrochloric acid, and the temperature is lowered to 10-30° C. and stirred for crystallization for 1-3 hours;

[0025] In the washing step, the crystals obtained in the crystallization step are filtered and washed with purified water to collect the filter cake;

[0026] In the drying step, the filter cake obtained after the washing step is dried under reduced pressure at 60-80° C. for 10-12 hours to obtain a crude torsemide product.

[0027] A preferred specific embodiment includes two crystallization steps and washing steps after the condensation reaction step, wherein after the first crystallization step and washing step, a dissolving step is performed, and then a second crystallization step and washing step are performed;

[0028] In the dissolving step, the filter cake obtained after the first crystallization step and the washing step is stirred and dissolved in a sodium hydroxide aqueous solution with a pH of 10±0.5, and the filtrate is collected after filtering, and the filtrate is subjected to a second crystallization step and a washing step;

[0029] After the second crystallization step and the washing step, the drying step is performed.

[0030] Example 3

[0031] Based on Example 1-2, this example further includes a synthesis step of a first intermediate, wherein the synthesis step of the first intermediate is as follows: Figure 3 , specifically including the following steps:

[0032] S1. Add the second intermediate, m-toluidine and methanol into a reaction kettle, and stir the reaction at 45-55° C. for at least 3 hours; the second intermediate is 4-chloropyridine-3-sulfonamide;

[0033] S2 is cooled to 10-30°C, the pH is adjusted to 7-8 with sodium hydroxide solution, and the temperature is controlled at 10-30°C and stirred for crystallization for 1 hour;

[0034] S3: The crystals precipitated from S2 are filtered, washed, and dried under reduced pressure to obtain the first intermediate.

[0035] Example 4

[0036] Based on embodiments 1-3, this embodiment also includes Figure 4 The synthesis step of the second intermediate shown in the figure, the synthesis step of the second intermediate specifically comprises the following steps:

[0037] S11 Add phosphorus oxychloride, phosphorus pentachloride and 4-hydroxypyridine-3-sulfonic acid into the reaction kettle, control the temperature at 80±5℃ and stir to react for at least 4h;

[0038] S12: the reaction solution obtained in S11 is concentrated under reduced pressure at 60-80° C. until no liquid is evaporated;

[0039] S13. Add dichloromethane to the concentrate obtained in S12, stir evenly, control the temperature to below 30° C., slowly add purified water at 0-10° C., stir well, stand for stratification, collect the organic phase, and obtain an intermediate solution;

[0040] S14: adding the organic phase obtained in S13 to aqueous ammonia, controlling the temperature to 10-30° C. and stirring the reaction for at least 2 hours;

[0041] S14: adjusting the pH of the reaction product of S13 to 8.0-8.5 with an appropriate amount of ammonia water, controlling the temperature to 10-30° C., stirring and crystallizing for 1 hour, and then filtering, washing, and drying under reduced pressure in sequence to obtain the second intermediate.

[0042] Example 5

[0043] In some embodiments based on embodiments 1-4, the torsemide crude product synthesis step further comprises the following steps: Figure 5 The refining step comprises the following steps:

[0044] S21 Add N,N-dimethylformamide to the crude torsemide and stir to dissolve,

[0045] S22: slowly add purified water to the crude torsemide N,N-dimethylformamide solution, and stir to crystallize at 20-30°C for 1 hour;

[0046] S23: Filter the crystals precipitated from S32, wash the filter cake with purified water, collect the filter cake, and dry the filter cake under reduced pressure at 60-80° C. for 10-12 h to obtain the finished torsemide product.

[0047] In the above embodiments, some preferred embodiments are as follows: in the condensation reaction step of the torsemide crude product synthesis step, triethylamine, acetone and the first intermediate are fed in a molar ratio of 2:2:1.

[0048] In the step of synthesizing the first intermediate, m-toluidine and the second intermediate are fed in a molar ratio of 1.2:1, and the feeding ratio of the second intermediate to methanol is 1:5 (g / V).

[0049] In the synthesis step of the second intermediate, phosphorus oxychloride, phosphorus pentachloride and 4-hydroxypyridine-3-sulfonic acid are fed in a molar ratio of 7.5:2:1, the feeding ratio of 4-hydroxypyridine-3-sulfonic acid to aqueous ammonia is 1:1 (g / V), and the feeding ratio of 4-hydroxypyridine-3-sulfonic acid to dichloromethane is 1:8 (g / V).

[0050] Example 6

[0051] This embodiment is the best embodiment. The synthesis of torsemide uses 4-hydroxypyridine-3-sulfonic acid (SM1) as a starting material, and obtains 4-chloro-3-pyridinesulfonamide through chlorination and ammoniation (the synthesis step of the second intermediate); the second intermediate undergoes a substitution reaction with m-toluidine (SM2) to obtain a first intermediate (the synthesis step of the first intermediate); the first intermediate undergoes a condensation reaction with isopropyl isocyanate (SM3) to obtain torsemide (condensation reaction step); and a purification step.

[0052] The synthetic route is as follows.

[0053]

[0054] This synthetic route has the advantages of:

[0055] 1. The route is mature, the process reaction is simple, and it is easy to operate;

[0056] 2. The solvents in the route are commonly used and cheap, the yield of each step of the reaction is high, and the industrialization cost is low.

[0057] This embodiment produces finished products in batches of 3±0.2 kg with batch numbers: 220601, 220602, and 220603, and performs detection tests of related substances and stability tests on each batch of finished products.

[0058] The synthesis steps of the second intermediate are as follows:

[0059] Add 19.7 kg of phosphorus oxychloride (POCl3) to a 50L double-layer glass reactor, and then slowly add 7.1 kg of phosphorus pentachloride (PCl5) and 3.0 kg of 4-hydroxypyridine-3-sulfonic acid (SM1). After the addition is completed, the reaction solution is heated to 80±5°C, stirred for 4 hours, and the reaction progress is monitored by TLC (see TLC monitoring method 1).

[0060] After the reaction is completed, the reaction solution is concentrated under reduced pressure at 60-80°C until no liquid evaporates. 24.0L of dichloromethane is added to the concentrate, stirred evenly, the temperature is controlled to below 30°C, and slowly added to 30.0L of purified water pre-cooled to 0-10°C, stirred thoroughly, allowed to stand and stratified, and the organic phase is collected to obtain an intermediate solution.

[0061] The organic phase was added to 3.0 L of aqueous ammonia. After the addition was complete, the temperature was controlled to 10-30° C. and stirred for reaction for 2 h. The reaction progress was monitored by TLC (see TLC monitoring method 2).

[0062] After the reaction is completed, adjust the pH of the system to 8.0-8.5 with an appropriate amount of ammonia water, control the temperature to 10-30°C, stir and crystallize for 1 hour, filter, wash the filter cake with 6.0L purified water, collect the filter cake, and dry it under reduced pressure at 50-70°C for 8-12 hours to obtain intermediate I.

[0063] (1) Yield range: 70-80%.

[0064] (2) TLC monitoring method:

[0065] TLC monitoring method 1:

[0066] Developing solvent: petroleum ether-ethyl acetate (5:1);

[0067] Detection wavelength: UV254nm;

[0068] End point indication: no SM1 UV spot on the TLC plate.

[0069] TLC monitoring method 2:

[0070] Developing solvent: petroleum ether-ethyl acetate (5:1);

[0071] Detection wavelength: UV254nm;

[0072] End point indication: no intermediate UV spot on the TLC plate.

[0073] (3) Storage: Keep in a cool place away from light.

[0074] Table 1. List of materials used in the synthesis of the second intermediate

[0075]

[0076] The synthesis steps of the first intermediate are as follows:

[0077] Add 2.4 kg of intermediate I, 1.6 kg of m-toluidine and 12.0 L of methanol into a 50 L double-layer glass reactor, heat to 45-55 °C and stir for 3 h, and monitor the reaction progress by TLC (see TLC monitoring method).

[0078] After the reaction is completed, the reaction solution is cooled to 10-30°C, 7.2L of purified water is added, the pH is adjusted to 7-8 with 20% sodium hydroxide solution, the temperature is controlled to 10-30°C, and stirred for crystallization for 1h. Filter, wash the filter cake with 4.8L of purified water, collect the filter cake, and dry it under reduced pressure at 60-70°C for 10-12h to obtain intermediate II.

[0079] ① Yield range: 90-100%.

[0080] ②TLC monitoring method:

[0081] Developing solvent: dichloromethane-methanol (14:1);

[0082] Detection wavelength: UV254nm;

[0083] End point indication: no UV spot of intermediate I on the TLC plate.

[0084] ③Storage: Store at room temperature.

[0085] Table 2. List of materials used in the synthesis of the first intermediate

[0086]

[0087] The condensation reaction steps are as follows:

[0088] Add 3.0 kg of intermediate II, 2.3 kg of triethylamine and 9.0 L of acetone to a 50 L double-layer glass reactor, stir evenly, and then slowly add 1.9 kg of isopropyl isocyanate (SM3). After the addition is completed, control the temperature to 40-50 ° C and stir for 6 hours, and monitor the reaction progress by TLC.

[0089] After the reaction is completed, the pH of the system is adjusted to 4±0.2 with 4N hydrochloric acid, and the temperature is lowered to 10-30°C and stirred for crystallization for 3 hours. The filter cake is filtered and washed with 2.0L purified water, and the filter cake is collected.

[0090] The filter cake and 66.0L purified water were added to a 100L double-layer glass reactor in sequence, and 20% sodium hydroxide was added to adjust the pH to 10±0.5, stirred to dissolve, filtered, and the filtrate was collected. The pH of the filtrate was adjusted to 4±0.2 with 4N hydrochloric acid, and the temperature was controlled to 10-30°C and stirred for crystallization for 1h. Filter, wash the filter cake with 6.0L purified water, collect the filter cake, and dry it under reduced pressure at 60-80°C for 10-12h to obtain the crude torsemide.

[0091] ①Yield range: 80%-90%.

[0092] ②TLC monitoring method:

[0093] Developing solvent: dichloromethane-methanol (14:1);

[0094] Detection wavelength: UV254nm;

[0095] End point indication: no UV spot of intermediate II on the TLC plate.

[0096] ③Storage: Keep in a light-proof, sealed, dry place.

[0097] Table 3. List of materials used in the synthesis of crude products

[0098]

[0099] The refining steps are as follows:

[0100] Add 3.3 kg of crude product and 19.8 L of DMF to a 100 L double-layer glass reactor, stir to dissolve, slowly add 39.6 L of purified water, control the temperature to 20-30 ° C, stir and crystallize for 1 hour. Filter, wash the filter cake with 13.2 L of purified water, collect the filter cake, and dry it under reduced pressure at 60-80 ° C for 10-12 hours to obtain the finished torsemide. Yield range: 90%-100%.

[0101] Table 4. List of materials used in the refining steps

[0102]

[0103] Table 5: List of main production equipment

[0104]

[0105]

[0106] Note: Batch range is calculated based on finished products.

[0107] Comparative Example 1

[0108] The only difference in Example 6 is that the temperature and time of the synthetic chlorination reaction of the intermediate I are adjusted to: 80-110°C, 4-8h. It is found that the temperature is too high and the time is too long, resulting in increased production costs and increased safety risks. The advantages of the finished product are not obvious compared with Example 6.

[0109] Comparative Example 2

[0110] The synthesis method of the key intermediate of torasemide disclosed in Chinese patent ZL202210090539.5, the yield of the intermediate 4-m-toluidine pyridine-3-sulfonamide in Examples 8-9 is 62-87.3%. No detailed related substance detection results are found, and no stability test results are found.

[0111] Comparative Example 3

[0112] The solution of Document 1 replaces isopropyl isocyanate with methyl isopropylcarbamate, thereby reducing the cost and increasing the yield to 37.9%.

[0113]

[0114]

[0115]

[0116] Test Example 2 Stability Test

[0117] According to the relevant guidelines such as the "Guidelines for Stability Testing of APIs and Pharmaceutical Preparations" (General Rules 9001 of Part IV of the 2020 Edition of the Chinese Pharmacopoeia), the "Technical Guidelines for Stability Studies of Chemical Drugs (APIs and Preparations) (Revised)", and with reference to the relevant provisions of the torasemide quality standard, the finished product properties, related substances 1, related substances 2, moisture, bacterial endotoxins, microbial limits, content determination and other items of Example 6 were investigated for stability. The sample information for the stability test is shown in Table 7.

[0118] Table 7. Test sample information

[0119]

[0120] Table 8 Stability test results

[0121]

[0122]

[0123] According to the quality standard of torasemide, three batches of pilot batch samples (batch numbers: 220601, 220602, and 220603) were subjected to accelerated (40°C ± 2°C / 75% ± 5% RH) and long-term (30°C ± 2°C / 65% ± 5% RH) stability tests. After 6 months of accelerated and 6 months of long-term stability tests, the test results of each item met the quality standard requirements. According to the stability test conditions and results, and combined with the quality standard of torasemide in the 2020 edition of the Chinese Pharmacopoeia, the storage conditions of this product are set as light-shielding and sealed, and the shelf life is tentatively set at 36 months. The test results are shown in Table 9.

[0124] Table 9. Test results

[0125]

[0126] (1) Based on the existing stability studies, continue to complete the long-term 9, 12, 18, 24, and 36 month studies of the pilot batches (Batch Nos.: 220601, 220602, and 220603) and inspect them according to the torsemide quality standard; complete the long-term and accelerated stability studies of the validation batches (Batch Nos.: 221201, 221202, and 221203) and inspect them according to the torsemide quality standard.

[0127] (2) Stability tests were conducted on production-scale products. The products were placed at a temperature of 30°C ± 2°C and a relative humidity of 65% ± 5% RH according to the proposed packaging conditions (polyester / aluminum / polyethylene composite film and bags for pharmaceutical packaging). Samples were taken for inspection at 3, 6, 9, 12, 18, 24, and 36 months. The results all met the requirements of relevant national standards.

[0128] Although the present invention has been described in detail above by general description, specific implementation methods and experiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.

Claims

1. A method for producing torasemide, characterized in that: The method comprises a step of synthesizing a crude torsemide, wherein the step of synthesizing the crude torsemide comprises a condensation reaction step of reacting a first intermediate with isopropyl isocyanate to obtain the crude torsemide; The first intermediate is 4-(3-methylphenyl)aminopyridine-3-sulfonamide; The condensation reaction step specifically includes the following steps: after uniformly mixing triethylamine, acetone and the first intermediate in a reaction kettle, slowly adding isopropyl isocyanate, controlling the temperature to 40-50° C. and stirring the reaction for at least 6 hours.

2. The method for producing torasemide according to claim 1, characterized in that: In the torasemide crude product synthesis step, after the condensation reaction step, a crystallization step, a washing step, and a drying step are also included; In the crystallization step, the pH of the system is adjusted to 4±0.2 with 4N hydrochloric acid, and the temperature is lowered to 10-30° C. and stirred for crystallization for 1-3 hours; In the washing step, the crystals obtained in the crystallization step are filtered and washed with purified water to collect the filter cake; In the drying step, the filter cake obtained after the washing step is dried under reduced pressure at 60-80° C. for 10-12 hours to obtain a crude torsemide product.

3. The method for producing torasemide according to claim 2, characterized in that: In the torasemide crude product synthesis step, after the condensation reaction step, two crystallization steps and washing steps are included, and after the first crystallization step and washing step, a dissolving step is performed, and then a second crystallization step and washing step are performed; In the dissolving step, the filter cake obtained after the first crystallization step and the washing step is stirred and dissolved in a sodium hydroxide aqueous solution with a pH of 10±0.5, and the filtrate is collected after filtering, and the filtrate is subjected to a second crystallization step and a washing step; After the second crystallization step and the washing step, the drying step is performed.

4. The method for producing torasemide according to claim 1, characterized in that: The method further comprises a step of synthesizing a first intermediate, wherein the step of synthesizing the first intermediate specifically comprises the following steps: S1. Add the second intermediate, m-toluidine and methanol into a reaction kettle, and stir the reaction at 45-55° C. for at least 3 hours; the second intermediate is 4-chloropyridine-3-sulfonamide; S2 is cooled to 10-30°C, the pH is adjusted to 7-8 with sodium hydroxide solution, and the temperature is controlled at 10-30°C and stirred for crystallization for 1 hour; S3: The crystals precipitated from S2 are filtered, washed, and dried under reduced pressure to obtain the first intermediate.

5. The method for producing torasemide according to claim 4, characterized in that: The method further includes a step of synthesizing a second intermediate, wherein the step of synthesizing the second intermediate specifically includes the following steps: S11 Add phosphorus oxychloride, phosphorus pentachloride and 4-hydroxypyridine-3-sulfonic acid into the reaction kettle, control the temperature at 80±5℃ and stir to react for at least 4h; S12: the reaction solution obtained in S11 is concentrated under reduced pressure at 60-80° C. until no liquid is evaporated; S13. Add dichloromethane to the concentrate obtained in S12, stir evenly, control the temperature to below 30° C., slowly add purified water at 0-10° C., stir well, stand for stratification, collect the organic phase, and obtain an intermediate solution; S14: adding the organic phase obtained in S13 to aqueous ammonia, controlling the temperature to 10-30° C. and stirring the reaction for at least 2 hours; S14: adjusting the pH of the reaction product of S13 to 8.0-8.5 with an appropriate amount of ammonia water, controlling the temperature to 10-30° C., stirring and crystallizing for 1 hour, and then filtering, washing, and drying under reduced pressure in sequence to obtain the second intermediate.

6. The method for producing torasemide according to claim 1, characterized in that: The torasemide crude product synthesis step further includes a refining step, and the refining step includes the following steps: S21 Add N,N-dimethylformamide to the crude torsemide and stir to dissolve, S22: slowly add purified water to the crude torsemide N,N-dimethylformamide solution, and stir to crystallize at 20-30°C for 1 hour; S23: Filter the crystals precipitated from S32, wash the filter cake with purified water, collect the filter cake, and dry the filter cake under reduced pressure at 60-80° C. for 10-12 h to obtain the finished torsemide product.

7. The method for producing torasemide according to claim 1, characterized in that: In the condensation reaction step of the torasemide crude product synthesis step, triethylamine, acetone and the first intermediate are fed in a molar ratio of 2:2:

1.

8. The method for producing torasemide according to claim 4, characterized in that: In the step of synthesizing the first intermediate, m-toluidine and the second intermediate are fed in a molar ratio of 1.2:1, and the feeding ratio of the second intermediate to methanol is 1:5 (g / V).

9. The method for producing torasemide according to claim 5, characterized in that: In the synthesis step of the second intermediate, phosphorus oxychloride, phosphorus pentachloride and 4-hydroxypyridine-3-sulfonic acid are fed in a molar ratio of 7.5:2:1, the feeding ratio of 4-hydroxypyridine-3-sulfonic acid to aqueous ammonia is 1:1 (g / V), and the feeding ratio of 4-hydroxypyridine-3-sulfonic acid to dichloromethane is 1:8 (g / V).

10. The method for producing torasemide according to claim 1, characterized in that: The torsemide production method uses 4-hydroxypyridine-3-sulfonic acid as a starting material, and sequentially undergoes chlorination and ammoniation to obtain a second intermediate; the second intermediate undergoes a substitution reaction with m-toluidine to obtain a first intermediate; the first intermediate undergoes the torsemide crude product synthesis step to obtain the torsemide crude product. Wherein, the second intermediate is 4-chloropyridine-3-sulfonamide; The first intermediate is 4-(3-methylphenyl)aminopyridine-3-sulfonamide; The synthetic route of the production method of torasemide is as follows: